Aclidinium bromide for the treatment of chronic obstructive pulmonary disease (Q38066977)

28 August 2017

1 reference

title

Aclidinium bromide for the treatment of chronic obstructive pulmonary disease (English)

1 reference

chronic obstructive pulmonary disease

28 August 2017

main subject

1 reference

Vandana Gupta

1 reference

28 August 2017

Dave Singh

series ordinal

1 reference

28 August 2017

language of work or name

1 reference

1 December 2012

1 reference

Expert Review of Respiratory Medicine

28 August 2017

published in

1 reference

28 August 2017

1 reference

28 August 2017

1 reference

28 August 2017

page(s)

581-588

1 reference

Epidemiology and costs of chronic obstructive pulmonary disease.

28 August 2017

cites work

1 reference

COPD exacerbations: defining their cause and prevention

21 January 2018

1 reference

Pharmacologic interventions in chronic obstructive pulmonary disease: bronchodilators

21 January 2018

1 reference

A 4-year trial of tiotropium in chronic obstructive pulmonary disease

21 January 2018

1 reference

Cholinergic pathways in the lungs and anticholinergic therapy for chronic obstructive pulmonary disease

21 January 2018

1 reference

Combination of formoterol and tiotropium in the treatment of COPD: effects on lung function

21 January 2018

1 reference

Presence, distribution and physiological function of adrenergic and muscarinic receptor subtypes in the human heart

21 January 2018

1 reference

Muscarinic receptors: their distribution and function in body systems, and the implications for treating overactive bladder

21 January 2018

1 reference

Pharmacological regulation of the neuronal control of airway mucus secretion

21 January 2018

1 reference

Activation of muscarinic receptors by non-neuronal acetylcholine

21 January 2018

1 reference

Muscarinic receptor signaling in the pathophysiology of asthma and COPD.

21 January 2018

1 reference

Tiotropium bromide (Ba 679 BR), a novel long-acting muscarinic antagonist for the treatment of obstructive airways disease

21 January 2018

1 reference

Ba 679 BR, a novel long-acting anticholinergic bronchodilator

21 January 2018

1 reference

Tiotropium bromide. A review of its use as maintenance therapy in patients with COPD.

21 January 2018

1 reference

A long-term evaluation of once-daily inhaled tiotropium in chronic obstructive pulmonary disease

21 January 2018

1 reference

Inhaled anticholinergics and risk of major adverse cardiovascular events in patients with chronic obstructive pulmonary disease: a systematic review and meta-analysis

21 January 2018

1 reference

Mortality associated with tiotropium mist inhaler in patients with chronic obstructive pulmonary disease: systematic review and meta-analysis of randomised controlled trials

21 January 2018

1 reference

Tiotropium in combination with placebo, salmeterol, or fluticasone-salmeterol for treatment of chronic obstructive pulmonary disease: a randomized trial

21 January 2018

1 reference

Discovery of novel quaternary ammonium derivatives of (3R)-quinuclidinol esters as potent and long-acting muscarinic antagonists with potential for minimal systemic exposure after inhaled administration: identification of (3R)-3-{[hydroxy(di-2-thien

21 January 2018

1 reference

Characterization of aclidinium bromide, a novel inhaled muscarinic antagonist, with long duration of action and a favorable pharmacological profile.

21 January 2018

1 reference

Aclidinium bromide, a new, long-acting, inhaled muscarinic antagonist: in vitro plasma inactivation and pharmacological activity of its main metabolites.

21 January 2018

1 reference

Identification of the human enzymes responsible for the enzymatic hydrolysis of aclidinium bromide

21 January 2018

1 reference

Lung deposition of aclidinium bromide from Genuair, a multidose dry powder inhaler.

21 January 2018

1 reference

Peak inspiratory flow through the Genuair inhaler in patients with moderate or severe COPD.

21 January 2018

1 reference

Safety and Tolerability of Aclidinium Administered Intravenously and Absolute Bioavailability of Inhaled Aclidinium in Healthy Male Participants

21 January 2018

1 reference

Bronchodilatory effects of aclidinium bromide, a long-acting muscarinic antagonist, in COPD patients

21 January 2018

1 reference

Aclidinium bromide provides long-acting bronchodilation in patients with COPD.

21 January 2018

1 reference

Efficacy and safety of once-daily aclidinium in chronic obstructive pulmonary disease

21 January 2018

1 reference

Outcomes for COPD pharmacological trials: from lung function to biomarkers.

21 January 2018

1 reference

Efficacy of aclidinium bromide 400 μg twice daily compared with placebo and tiotropium in patients with moderate to severe COPD.

21 January 2018

1 reference

A randomised, placebo- and active-controlled dose-finding study of aclidinium bromide administered twice a day in COPD patients

21 January 2018

1 reference

Efficacy and safety of a 12-week treatment with twice-daily aclidinium bromide in COPD patients (ACCORD COPD I).

21 January 2018

1 reference

Onset of effect of aclidinium, a novel, long-acting muscarinic antagonist, in patients with COPD.

21 January 2018

1 reference

Aclidinium bromide improves exercise endurance and lung hyperinflation in patients with moderate to severe COPD.

21 January 2018

1 reference

Effects of tiotropium on lung hyperinflation, dyspnoea and exercise tolerance in COPD.

21 January 2018

1 reference

Enhanced persistence with tiotropium compared with other respiratory drugs in COPD.

21 January 2018

1 reference

Efficacy and safety of once-daily NVA237 in patients with moderate-to-severe COPD: the GLOW1 trial

21 January 2018

1 reference

The efficacy and safety of the novel long-acting β2 agonist vilanterol in patients with COPD: a randomized placebo-controlled trial

21 January 2018

1 reference

QVA149 demonstrates superior bronchodilation compared with indacaterol or placebo in patients with chronic obstructive pulmonary disease

21 January 2018

1 reference

Inhaled Anticholinergic Drug Therapy and the Risk of Acute Urinary Retention in Chronic Obstructive Pulmonary Disease

21 January 2018

1 reference

Efficacy and safety of twice-daily aclidinium bromide in COPD patients: the ATTAIN study

21 January 2018

1 reference

21 January 2018

Identifiers

DOI

10.1586/ERS.12.61

1 reference

28 August 2017

1 reference